Prodrugs of substituted amino heterobicycles which modulate the function of the vanilloid-1 receptor (vr1)

Promedicaments d'heterobicycles amino substitues destines a la modulation de la fonction du recepteur vanilloide 1 (vr1)

Abstract

Compounds of formula (I) which are useful as therapeutic compounds, particularly in the treatment of pain and other conditions ameliorated by the modulation of the function of the vanilloid-1 receptor (VR1).
L'invention concerne des composés de formule (I) utilisés en tant que composés thérapeutiques, notamment, dans le traitement de la douleur et d'autres troubles améliorés par la modulation de la fonction du récepteur vanilloïde 1 (VR1).

Claims

Description

Topics

Download Full PDF Version (Non-Commercial Use)

Patent Citations (2)

    Publication numberPublication dateAssigneeTitle
    WO-03062209-A2July 31, 2003Neurogen CorporationAnalogues de quinazoline-4-ylamine substitues
    WO-2004074290-A1September 02, 2004Merck Sharp & Dohme LimitedAmino-heterocycles substitues en tant qu’antagonistes du vr-1 pour traiter la douleur

NO-Patent Citations (0)

    Title

Cited By (13)

    Publication numberPublication dateAssigneeTitle
    DE-102009004245-A1July 15, 2010Bayer Schering Pharma AktiengesellschaftNeue anellierte, Heteroatom-verbrückte Pyrazol- und Imidazol-Derivate und ihre Verwendung
    EP-2578583-A1April 10, 2013Amgen Inc.Kondensierte heterocyclische Derivate und Verwendungsverfahren
    FR-2911605-A1July 25, 2008Sanofi Aventis SaNew pyrrolopyridine derivatives useful for treating pain, inflammation, metabolic disorders, urological disorders, gynecological disorders, gastrointestinal disorders, respiratory disorders, psoriasis, pruritis
    US-7875627-B2January 25, 2011Abbott LaboratoriesThienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof
    US-8044066-B2October 25, 2011Sanofi-AventisDerivatives of pyrrolopyridine-2-carboxamides, preparation thereof and therapeutic application thereof
    US-8309551-B2November 13, 2012Bayer Intellectual Property GmbhPyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivatives as stimulators of guanylate cyclase for cardiovascular disorders
    US-8334291-B2December 18, 2012Bayer Intellectual Property GmbhAliphatically substituted pyrazolopyridines, and the use thereof
    US-8501769-B2August 06, 2013Abbvie Inc.Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof
    WO-2006063178-A2June 15, 2006Abbott LaboratoriesThienopyridyl compounds that inhibit vanilloid receptor subtype 1 (vr1) and uses thereof
    WO-2006063178-A3August 24, 2006Abbott Lab, Arthur R Gomtsyan, Tammie K Jinkerson, Chih-Hung Lee, Sean C TurnerComposes de thienopyridyle inhibiteurs du recepteur de vanilloide de sous type 1 (vr1) et utilisations afferentes
    WO-2008107543-A2September 12, 2008Sanofi-AventisDerivatives of pyrrolopyridine-2-carboxamids, preparation thereof and therapeutic application thereof
    WO-2008107543-A3December 24, 2008Laurent Dubois, Yannick Evanno, Andre Malanda, Sanofi AventisDerives de pyrrolopyridine-2-carboxamides, leur preparation et leur application en therapeutique
    WO-2010079120-A1July 15, 2010Bayer Schering Pharma AktiengesellschaftBenzimidazole and pyrazolopyridine derivatives for treating and/or preventing cardiovascular diseases